Home  >  News
you can get e-magazine links on WhatsApp. Click here
Corporate + Font Resize -

Biocon Sdn. Bhd. enters Malaysia Book of Records as the first & the largest integrated insulin manufacturing facility

Our Bureau, Bengaluru
Friday, August 5, 2022, 14:20 Hrs  [IST]

Biocon Sdn. Bhd., Malaysia, a subsidiary of Biocon Biologics Ltd (BBL), announced that it has entered the prestigious Malaysia Book of Records.
The 562,000 sq. ft. facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR, which officially recognizes record-creating and record-breaking achievements in the fields of human endeavour, building & structures, transportation, arts & entertainment, business, sports & games, science & technology, nature etc. in Malaysia.
Kiran Kumar Gandhirajan, site head, Malaysia, said: “We are extremely proud and honoured to be named in the Malaysia Book of Records, which is a recognition of the scale of our operations in the region. As the only insulin manufacturer in Malaysia, we have been able to achieve insulin self-sufficiency and improve insulin access while providing savings to our partner, Ministry of Health (MoH), Malaysia. Through the insulins manufactured at this facility, Biocon Biologics is also making a difference to the lives of millions of people with diabetes worldwide in line with our aspiration of taking our biosimilar insulins to ‘one in five’ insulin-dependent patients.”
“I would like to acknowledge the remarkable work being done by the team in Malaysia to address the global need for high quality insulins at affordable prices through our Centre of Excellence (CoE) for insulins in Malaysia,” he added.
Biocon Biologics has created a Centre of Excellence (CoE) for insulins in Malaysia with end-to-end capabilities to manufacture a broad portfolio of regular, basal and rapid insulins. The state-of-the-art insulins facility in Johor is the first and only biopharmaceutical sterile injectables facility in Malaysia to receive US Food and Drug Administration (FDA) and European Medicines Agency approvals. More recently, Biocon’s biosimilar insulin Glargine made at Malaysia received a historic US FDA approval as the ‘first interchangeable biosimilar’.
Through Biocon Sdn Bhd, Biocon Biologics has set up Asia’s largest integrated insulin manufacturing and R&D facility in Malaysia at an investment of over USD 350 million. This is the largest foreign investment in biotechnology in Malaysia, reflecting Biocon Biologics’ commitment to put affordable life-changing insulins within the reach of patients across the world. Biocon Biologics is providing affordable access to these life-saving therapies to patients in many developed markets like US, EU, Australia, as well as many emerging market countries in the Middle East and Latin America through its scientifically validated, high quality human insulin and analog products manufactured at the facility in Johor, Malaysia.
Commercial operations at the facility commenced in 2016 when Biocon Biologics’ recombinant human insulin became the first locally manufactured biosimilar product approved for sale in Malaysia.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |